Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,570 result(s) found for: Bone Cancer. Displaying page 2 of 179.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-005999-13 Sponsor Protocol Number: D8180C00034 Start Date*: 2008-02-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomised, Open-label, Pilot Study to Evaluate the Safety and the Effects on Bone Resorption of AZD0530 in Patients with Prostate Cancer or Breast Cancer with Metastatic Bone Disease ...
    Medical condition: Prostate Cancer or Breast Cancer with Metastatic Bone Disease Cáncer de próstata o de mama con metástasis óseas
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) SE (Completed) PT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-000885-20 Sponsor Protocol Number: Ibondronate Start Date*: 2007-07-20
    Sponsor Name:academic hospital Maastricht
    Full Title: Open label study to establish the efficacy of intravenous loading doses of Ibandronate 6 mg in patients with lung cancer and skeletal metastased experiencing moderate to severe bone pain.
    Medical condition: Patients with lung cancer and malignant disease to bone.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005485-37 Sponsor Protocol Number: 20050147 Start Date*: 2006-06-05
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer
    Medical condition: Castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) GB (Completed) CZ (Completed) BE (Completed) IE (Completed) SK (Completed) HU (Completed) ES (Completed) PT (Completed) DE (Completed) IT (Completed) LT (Completed) LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-002415-10 Sponsor Protocol Number: PROCoMBO Start Date*: 2014-02-11
    Sponsor Name:University Medical Center Groningen
    Full Title: [18F]-labelled FDHT in PET/CT for detection and staging of bone metastases in hormone naïve prostate cancer
    Medical condition: Hormone naive prostate cancer, metastasized to bone (2 or more bone metastases).
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002132-94 Sponsor Protocol Number: CZOL446EDE28 Start Date*: 2008-08-18
    Sponsor Name:Novartis Pharma GmbH
    Full Title: „Effect of intravenous Zoledronic Acid on Bone Metabolism given over 4 month in patients with prostate cancer or breast cancer and bone metastasis. A prospective, single-arm multicenter study” (Z...
    Medical condition: Patients with prostate or breast cancer with bone metastasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036910 Prostate cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002418-12 Sponsor Protocol Number: CFEM345D2407 Start Date*: 2005-01-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, randomized, multicenter safety study to evaluate the skeletal and lipid profile effects of letrozole and tamoxifen in postmenopausal women with resected, receptor positive early brea...
    Medical condition: Bone loss attributed to cessation of ovarian estrogen production is common in postmenopausal women. In postmenopausal women with breast cancer, treatment with an aromatase inhibitor may further red...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001395-38 Sponsor Protocol Number: CALIPSO-study Start Date*: 2017-08-03
    Sponsor Name:AZIENDA USL DELLA VALLE D'AOSTA
    Full Title: Treatment of Metastatic prostate cancer castration resistant (mCRPC) with 223RaCl2: response evaluation with a novel tracer 68Ga-PSMA PET molecular imaging
    Medical condition: Patients mCRPC eligible to treatment with 223RaCl2
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005993 Bone metastases LLT
    20.1 100000004848 10036223 Positron emission tomography LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000981-46 Sponsor Protocol Number: IC2015-13 Start Date*: Information not available in EudraCT
    Sponsor Name:INSTITUT CURIE
    Full Title: First-line treatment of Ewing tumours with primary extrapulmonary dissemination in patients from 2 to 50 years -
    Medical condition: First-line treatment of Ewing tumours with primary extrapulmonary dissemination in patients from 2 to 50 years
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055101 Bone cancer metastatic PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002832-24 Sponsor Protocol Number: CZOL446GDE21 Start Date*: 2005-07-27
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor positive breast cancer and neoadjuvant or adjuvant chemoendocrine...
    Medical condition: Hormonreceptor positive breast cancer in premenopausal women
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002223-42 Sponsor Protocol Number: A4091061 Start Date*: 2015-10-12
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER ...
    Medical condition: Metastatic Bone Pain
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049038 Metastatic bone pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Completed) SK (Completed) HU (Completed) RO (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003258-25 Sponsor Protocol Number: X16120 Start Date*: 2019-07-04
    Sponsor Name:Odense University Hospital
    Full Title: Bone Study Bone Healing During Ninlaro Exposure. An open label phase 2 single centre clinical trial
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001376-12 Sponsor Protocol Number: BISMARK 2005 Start Date*: 2005-08-19
    Sponsor Name:University of Sheffield
    Full Title: Cost-effective use of BISphonphonates in metastatic bone disease - a comparison of bone MARKer directed zoledronic acid therapy to a standard schedule.
    Medical condition: Advanced breast cancer with bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001855-12 Sponsor Protocol Number: BO 18040 Start Date*: 2004-02-16
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Randomized, two arm, placebo controlled study to compare the efficacy of IV loading doses followed by maintenance treatment with IV ibandronic acid versus zoledronic acid in patients with skeletal ...
    Medical condition: Metastatic Bone Pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001854-10 Sponsor Protocol Number: BO18039 Start Date*: 2005-02-16
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Randomized, two arm, placebo controlled double dummy study to compare the efficacy of intravenous loading doses followed by maintenance treatment with oral ibandronic acid versus zoledronic acid in...
    Medical condition: Metastatic Bone Pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002692-42 Sponsor Protocol Number: 1.1_2011 Start Date*: 2012-06-20
    Sponsor Name:MUW-Medical University of Vienna,Medizinische Universität Wien
    Full Title: Characterization of myeloma bone lesions - before and during anti-cancer therapy - using 18F-FDG-, 18F-fluoride PET/CT and MRI- a pilot study
    Medical condition: The primary aim of this study is the characterization of WB MRI detected untreated MM bone lesions in consideration of the mineralization status and tumor activity using 18F-fluorid-PET/CT and 18F ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000697-74 Sponsor Protocol Number: ML20115 Start Date*: 2006-08-07
    Sponsor Name:The BONiFIN study group
    Full Title: A phase II, open label study to establish the safety and efficacy of intravenous loading dose of 3 x Bondronat 6 mg in 3 consecutive days in patients with breast cancer and skeletal metastases expe...
    Medical condition: Treatment of pain in breast cancer patients with bone metastases
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002407-25 Sponsor Protocol Number: 16996 Start Date*: 2014-11-25
    Sponsor Name:Bayer AG
    Full Title: A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride
    Medical condition: Castrate Resistant Prostate Cancer/Hormone-Refractory Prostate Cancer, breast cancer or multiple myeloma patients with bone metastasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036916 Prostate cancer stage D LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) ES (Completed) FR (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-001786-18 Sponsor Protocol Number: CZOL446GDE08 Start Date*: 2005-03-22
    Sponsor Name:EAU EUROPEAN ASSOCIATION OF UROLOGY
    Full Title: Effectiveness of Zometa treatment for the prevention of bone metastases in high risk prostate cancer patients. A randomized, open-label, multicenter study of the European Association of Urology (EA...
    Medical condition: Prevention of bone metastasis in high risk prostate cancer patients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003620-37 Sponsor Protocol Number: STH19580 Start Date*: 2019-10-31
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: NEPTUNE: Enhancement of immuNothEraPy combining avelumab and repeaT doses of radiUm-223 in ER+ve, HER2-ve metastatic breast caNcEr.
    Medical condition: ER+ve HER-ve breast cancer with bone metastases
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10006280 Breast neoplasm benign female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-003642-26 Sponsor Protocol Number: 3116001 Start Date*: 2014-12-17
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: SAFETY AND PHARMACOKINETICS OF ODM-204 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): OPEN, NONRANDOMISED, UNCONTROLLED, MULTICENTRE, DOSE ESCALATION, FIRST-IN-MAN STUDY W...
    Medical condition: Metastatic castration resistant prostate cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036916 Prostate cancer stage D LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) GB (Completed) LV (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 08:15:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA